Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227058 | 0.87 | MAPT (0.34) | MAPTKCNH2PTGDR2 | |
| SCHEMBL5229156 | 0.85 | P2RX7 (0.36) | MAPTKCNH2PTGDR2 | |
| SCHEMBL509302 | 0.85 | PTGDR2 (0.38) | MAPTKCNH2PTGDR2 | |
| SCHEMBL509197 | 0.85 | KCNH2 (0.37) | MAPTKCNH2PTGDR2 | |
| SCHEMBL509176 | 0.84 | KCNH2 (0.39) | MAPTKCNH2PTGDR2 | |
| SCHEMBL5229824 | 0.82 | MAPT (0.39) | MAPTKCNH2PTGDR2 | |
| SCHEMBL509505 | 0.81 | MAPT (0.37) | MAPTKCNH2PTGDR2 | |
| SCHEMBL5226744 | 0.81 | MAPT (0.37) | MAPTKCNH2PTGDR2 | |
| SCHEMBL5226712 | 0.81 | KCNH2 (0.38) | MAPTKCNH2PTGDR2 | |
| SCHEMBL5224587 | 0.80 | KCNH2 (0.40) | MAPTKCNH2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | MAPT 2150/4885KCNH2 3503/4885PTGDR2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.